share_log

Empower Clinics Signs Letter of Intent for $5 Million Equity Capital Facility and Provides Additional Corporate Updates

Empower Clinics Signs Letter of Intent for $5 Million Equity Capital Facility and Provides Additional Corporate Updates

Empower Clinics签署了500万美元股权资本融资的意向书,并提供了更多公司最新消息
Accesswire ·  2023/06/06 18:30

VANCOUVER, BC / ACCESSWIRE / June 6, 2023 / EMPOWER CLINICS INC (CSE:EPW) (PINK:EPWCF) ("Empower" or the "Company") an integrated healthcare company with a developing research and clinical trials divisions announces it has entered into a letter of intent with Crescita Capital LLC ("Crescita") for a CAD$5 million equity capital facility.

温哥华,BC/ACCESSWIRE/2023年6月6日/Empower Clinics Inc(CSE:EPW)(PINK:EPWCF)(“增强能力“或”公司“)一家拥有正在开发的研究和临床试验部门的综合保健公司宣布,它已经与Cresita Capital LLC(”Cresita“)就500万加元的股权资本融资签订了一份意向书。

Empower has entered into a letter of intent with Crescita for a CAD$5 million equity capital facility that Empower will have three (3) years to utilize to develop the business of the Company.

Empower已经与Cresita签署了一份意向书,将提供500万加元的股权资本融资,Empower将有三(3)年的时间来发展公司的业务。

The Letter of Intent (the "Letter of Intent") is intended to describe the present interest of Crescita and Empower to pursue a transaction whereby the Crescita commits to investing CAD$5 million (the "Commitment") in the Company by way of an equity drawdown facility (the "Proposed Transaction"). The terms of the Letter of Intent are not comprehensive and additional terms, including customary representations and warranties, will be incorporated into a definitive equity drawdown facility agreement (the "Definitive Agreement").

意向书(“意向书”)旨在描述Crescita目前的权益,并赋权进行一项交易,借此Crescita承诺以股权提取安排(“建议交易”)的方式向本公司投资500万加元(“承诺”)。意向书的条款并不全面,其他条款,包括惯常陈述及保证,将纳入最终股权提取融资协议(“最终协议”)。

The Commitment is intended to be used for general working capital purposes, strategic business development and expansion of clinical trial assets. The Commitment allows Empower to drawdown on the facility, at the discretion of the Company's management. The drawdowns are not mandatory, allowing Empower to selectively utilize this financing tool when capital is needed.

这项承诺旨在用于一般营运资本目的、战略业务发展和扩大临床试验资产。这一承诺允许授权在公司管理层酌情决定的情况下缩减设施。提款不是强制性的,允许Empower在需要资本时有选择地利用这一融资工具。

"We are thrilled with the opportunity to work with the Crescita team who have embraced Empowers path forward to becoming a Site Management Organization (SMO), with the goal of impacting the lives of patients through research and clinical trials." Said Steven McAuley, Empower Chairman & CEO. "Having access to flexible capital as and when the company requires allows us to plan for long term success with a growth strategy based on sustained cash flows."

我们很高兴有机会与Cresita团队合作,他们拥抱了EmPower成为一家网站管理组织(SMO)的道路,目标是通过研究和临床试验影响患者的生活。“Empower董事长兼首席执行官史蒂文·麦考利说。能够在公司需要时获得灵活的资本,使我们能够通过基于持续现金流的增长战略为长期成功制定计划。“

Mr. McAuley continues, "At the core the Company has always provided patient care, facility management and the administration of our healthcare professionals. These attributes are required to successfully manage sites for clinical trials. We play the all-important role of providing oversight, direction and support to the PI's and their patients ensuring the sites all operate within the guidelines of the study protocol as set by the sponsor and CRO."

McAuley先生继续说:“公司的核心一直是提供患者护理、设施管理和我们医疗保健专业人员的行政管理。这些属性是成功管理临床试验地点所必需的。我们扮演着向PI及其患者提供监督、指导和支持的重要角色,确保所有地点都在赞助商和CRO制定的研究方案的指导方针下运作。”

The Company also announces that it entered into debt settlement agreements with creditors on May 30th, 2023 for the settlement of debt in the aggregate amount of $68,900 CAD, which was settled through the issuance of an aggregate of 4,593,333 common shares in the capital of the Company (each, a "Share") at a deemed issue price of $0.015 per Share considered (the "Debt Settlement") and on June 1, 2023 the settlement of debt in the amount of $562.25 CAD, which was settled through the issuance of 37,483 Shares at a deemed price of $0.015 per Share.

该公司还宣布,它于5月30日与债权人签订了债务解决协议这是于2023年6月1日清偿总额为68,900加元的债务,以发行合共4,593,333股本公司股本中的普通股(每股为“股份”)的方式清偿(“债务清偿”),并于2023年6月1日清偿562.25加元的债务,清偿的方式为以每股0.015美元的价格发行37,483股普通股。

All Shares issued pursuant to the debt settlement have been issued with no hold period with prior written consent of the Canadian Securities Exchange. None of the Shares will be registered under the United States Securities Act of 1933, as amended, and none may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

根据债务结算发行的所有股票均已在事先获得加拿大证券交易所书面同意的情况下发行,没有持有期。任何股票都不会根据修订后的1933年美国证券法进行登记,如果没有登记或获得适用的豁免登记要求,任何股份都不能在美国发行或出售。本新闻稿不应构成出售或邀请购买公司任何证券的要约,也不应在任何司法管辖区出售任何此类要约、招揽或出售将是非法的证券。

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions, and engagement with management

本新闻稿可在AGORACOM上的授权诊所验证论坛上获取,以供股东讨论、提问和与管理层接触

To get enhanced access to investor information about Empower Clinics, please visit the download page to get your Empower Clinics Investor Experience Wallet Pass today.

要获取有关Empower诊所的投资者信息,请访问下载页面,今天即可获得Empower诊所投资者体验钱包通行证。

ABOUT EMPOWER:

关于授权

Empower is an integrated healthcare company with multi-disciplinary clinics, a Canadian medical device company and has launched its first clinical research site becoming a Site Management Organization (SMO) in Dallas, TX. Empower is a leader in integrated healthcare and research solutions and is reshaping the model for patient-first wellness.

Empower是一家拥有多学科诊所的综合性医疗保健公司,是一家加拿大医疗器械公司,并在德克萨斯州达拉斯推出了其首个临床研究网站,成为网站管理组织(SMO)。Empower是综合医疗和研究解决方案领域的领先者,正在重塑患者至上的健康模式。

ON BEHALF OF THE BOARD OF DIRECTORS:

我谨代表董事会:

Steven McAuley
Chief Executive Officer

史蒂文·麦考利
首席执行官

CONTACTS:

联系人:

Media:
Steven McAuley CEO s.mcauley@empowerclinics.com
+1 855-855-9058

媒体:
首席执行官Steven McAuley电子邮件:s.mcauley@empower Clinics.com
+1 855-855-9058

Investors:
Tamara Mason
Business Development & Communications
t.mason@empowerclinics.com
+1 855-855-9058

投资者:
塔玛拉·梅森
业务发展与沟通
邮箱:t.mason@empower Clinics.com
+1 855-855-9058

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

对前瞻性陈述的免责声明

This news release contains certain "forward-looking statements" or "forward-looking information" (collectively "forward looking statements") within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as "plans", "continues", "expects", "projects", "intends", "believes", "anticipates", "estimates", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include statements regarding: that the Company will impact the lives of patients through research and clinical trials, if at all. Such forward-looking statements are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the parties will be able to negotiate and enter into the Definitive Agreement on mutually agreeable terms; that legal and financial due diligence will be completed to the satisfaction of the parties; that all necessary third party approvals will be obtained. No assurance can be given that any of the events anticipated by the forward-looking statements will occur on the terms or in the time expected, or at all, or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

本新闻稿包含适用于加拿大证券法的某些“前瞻性陈述”或“前瞻性信息”(统称为“前瞻性陈述”)。除有关历史事实的陈述外,所有陈述均为前瞻性陈述,均基于截至本新闻稿发布之日的预期、估计和预测。前瞻性表述常常可以用“计划”、“继续”、“预期”、“项目”、“打算”、“相信”、“预期”、“估计”、“可能”、“将”、“潜在”、“建议”和其他类似词语,或某些事件或条件“可能”或“将”发生的信息来识别。本新闻稿中的前瞻性陈述包括以下陈述:公司将通过研究和临床试验影响患者的生活(如果有的话)。该等前瞻性表述基于管理层目前已知的假设,受风险和不确定因素的影响,可能会导致实际结果、业绩或发展与前瞻性表述中包含的内容大不相同,包括:双方将能够以相互同意的条款谈判和签订最终协议;法律和财务尽职调查的完成程度将令各方满意;将获得所有必要的第三方批准。不能保证前瞻性陈述中预期的任何事件将按照预期的条款或时间发生,或者根本不能保证,或者如果发生了,公司将从中获得什么好处。告诫读者不要过度依赖本新闻稿中的前瞻性陈述,这些前瞻性陈述完全受这些警告性陈述的限制。除适用的证券法明确要求外,公司没有义务更新或修改本新闻稿中的任何前瞻性陈述,除非适用的证券法明确要求,无论是由于新信息、未来事件还是其他原因。

SOURCE: Empower Clinics Inc.

资料来源:Empower Clinics Inc.


View source version on accesswire.com:
在accesswire.com上查看源代码版本:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发